Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndromes

T. De Witte, F. Zwaan, J. Hermans, J. Vernant, H. Kolb, J. Vossen, B. Lonnqvist, D. Beelen, A. Ferrant, J. Gmur, J. Liu Yin, X. Troussard, J. Cahn, M. Van Lint, A. Gratwohl

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

This retrospective survey of the EBMT Leukaemia Working Party describes 78 patients with myelodysplasia (MDS) or secondary acute myelogenous leukaemia (sAML) who were given an allogeneic bone marrow transplant (BMT). The status of underlying disease at the time of transplantation was prognostic for the two-year disease-free survival which was 60% for patients transplanted in complete remission. Similar results were obtained for those with less advanced MDS (50-64%) who had not received any prior intensive chemotherapy. The results were significantly less favourable for those with more advanced disease who only partially responded to prior intensive chemotherapy (18%) while none of those who either relapsed or were resistent to chemotherapy survived. Allogeneic BMT can therefore be considered as curative treatment for patients with MDS. Patients with sAML who have a histocompatible donor should be given chemotherapy intensive enough to induce complete remission. If this is achieved these individuals have a prognosis comparable to those with de novo AML in first remission after BMT.

Original languageEnglish
Pages (from-to)38-39
Number of pages2
JournalBone Marrow Transplantation
Volume4
Issue numberSUPPL. 3
Publication statusPublished - 1989

Fingerprint

Myelodysplastic Syndromes
Homologous Transplantation
Bone Marrow Transplantation
Leukemia
Drug Therapy
Bone Marrow
Transplants
Acute Myeloid Leukemia
Disease-Free Survival
Transplantation
Tissue Donors
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

De Witte, T., Zwaan, F., Hermans, J., Vernant, J., Kolb, H., Vossen, J., ... Gratwohl, A. (1989). Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndromes. Bone Marrow Transplantation, 4(SUPPL. 3), 38-39.

Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndromes. / De Witte, T.; Zwaan, F.; Hermans, J.; Vernant, J.; Kolb, H.; Vossen, J.; Lonnqvist, B.; Beelen, D.; Ferrant, A.; Gmur, J.; Liu Yin, J.; Troussard, X.; Cahn, J.; Van Lint, M.; Gratwohl, A.

In: Bone Marrow Transplantation, Vol. 4, No. SUPPL. 3, 1989, p. 38-39.

Research output: Contribution to journalArticle

De Witte, T, Zwaan, F, Hermans, J, Vernant, J, Kolb, H, Vossen, J, Lonnqvist, B, Beelen, D, Ferrant, A, Gmur, J, Liu Yin, J, Troussard, X, Cahn, J, Van Lint, M & Gratwohl, A 1989, 'Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndromes', Bone Marrow Transplantation, vol. 4, no. SUPPL. 3, pp. 38-39.
De Witte T, Zwaan F, Hermans J, Vernant J, Kolb H, Vossen J et al. Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndromes. Bone Marrow Transplantation. 1989;4(SUPPL. 3):38-39.
De Witte, T. ; Zwaan, F. ; Hermans, J. ; Vernant, J. ; Kolb, H. ; Vossen, J. ; Lonnqvist, B. ; Beelen, D. ; Ferrant, A. ; Gmur, J. ; Liu Yin, J. ; Troussard, X. ; Cahn, J. ; Van Lint, M. ; Gratwohl, A. / Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndromes. In: Bone Marrow Transplantation. 1989 ; Vol. 4, No. SUPPL. 3. pp. 38-39.
@article{eea691adc7124e42bc086fce8ad30c29,
title = "Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndromes",
abstract = "This retrospective survey of the EBMT Leukaemia Working Party describes 78 patients with myelodysplasia (MDS) or secondary acute myelogenous leukaemia (sAML) who were given an allogeneic bone marrow transplant (BMT). The status of underlying disease at the time of transplantation was prognostic for the two-year disease-free survival which was 60{\%} for patients transplanted in complete remission. Similar results were obtained for those with less advanced MDS (50-64{\%}) who had not received any prior intensive chemotherapy. The results were significantly less favourable for those with more advanced disease who only partially responded to prior intensive chemotherapy (18{\%}) while none of those who either relapsed or were resistent to chemotherapy survived. Allogeneic BMT can therefore be considered as curative treatment for patients with MDS. Patients with sAML who have a histocompatible donor should be given chemotherapy intensive enough to induce complete remission. If this is achieved these individuals have a prognosis comparable to those with de novo AML in first remission after BMT.",
author = "{De Witte}, T. and F. Zwaan and J. Hermans and J. Vernant and H. Kolb and J. Vossen and B. Lonnqvist and D. Beelen and A. Ferrant and J. Gmur and {Liu Yin}, J. and X. Troussard and J. Cahn and {Van Lint}, M. and A. Gratwohl",
year = "1989",
language = "English",
volume = "4",
pages = "38--39",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndromes

AU - De Witte, T.

AU - Zwaan, F.

AU - Hermans, J.

AU - Vernant, J.

AU - Kolb, H.

AU - Vossen, J.

AU - Lonnqvist, B.

AU - Beelen, D.

AU - Ferrant, A.

AU - Gmur, J.

AU - Liu Yin, J.

AU - Troussard, X.

AU - Cahn, J.

AU - Van Lint, M.

AU - Gratwohl, A.

PY - 1989

Y1 - 1989

N2 - This retrospective survey of the EBMT Leukaemia Working Party describes 78 patients with myelodysplasia (MDS) or secondary acute myelogenous leukaemia (sAML) who were given an allogeneic bone marrow transplant (BMT). The status of underlying disease at the time of transplantation was prognostic for the two-year disease-free survival which was 60% for patients transplanted in complete remission. Similar results were obtained for those with less advanced MDS (50-64%) who had not received any prior intensive chemotherapy. The results were significantly less favourable for those with more advanced disease who only partially responded to prior intensive chemotherapy (18%) while none of those who either relapsed or were resistent to chemotherapy survived. Allogeneic BMT can therefore be considered as curative treatment for patients with MDS. Patients with sAML who have a histocompatible donor should be given chemotherapy intensive enough to induce complete remission. If this is achieved these individuals have a prognosis comparable to those with de novo AML in first remission after BMT.

AB - This retrospective survey of the EBMT Leukaemia Working Party describes 78 patients with myelodysplasia (MDS) or secondary acute myelogenous leukaemia (sAML) who were given an allogeneic bone marrow transplant (BMT). The status of underlying disease at the time of transplantation was prognostic for the two-year disease-free survival which was 60% for patients transplanted in complete remission. Similar results were obtained for those with less advanced MDS (50-64%) who had not received any prior intensive chemotherapy. The results were significantly less favourable for those with more advanced disease who only partially responded to prior intensive chemotherapy (18%) while none of those who either relapsed or were resistent to chemotherapy survived. Allogeneic BMT can therefore be considered as curative treatment for patients with MDS. Patients with sAML who have a histocompatible donor should be given chemotherapy intensive enough to induce complete remission. If this is achieved these individuals have a prognosis comparable to those with de novo AML in first remission after BMT.

UR - http://www.scopus.com/inward/record.url?scp=0024948270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024948270&partnerID=8YFLogxK

M3 - Article

C2 - 2697398

AN - SCOPUS:0024948270

VL - 4

SP - 38

EP - 39

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - SUPPL. 3

ER -